Mathilde Marchand1, Patrick Brossard2, Henri Merdjan1, Nicola Lama2, Rolf Weitkunat3, Frank Lüdicke2. 1. Certara Strategic Consulting, Paris, France. 2. PMI R&D (Part of Philip Morris International Group of Companies), Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland. 3. PMI R&D (Part of Philip Morris International Group of Companies), Philip Morris Products S.A., Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland. rolf.weitkunat@pmi.com.
Abstract
BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal spray and oral nicotine gum. METHOD: Data from 4 single product use trials were used to develop a population pharmacokinetic model with Phoenix® NLME™ and to derive exposure parameters. Data from 4 separate ad libitum use studies were used for external validation. A total of 702 healthy adult smokers (54% males; 21-66 years of age; smoking ≥10 cigarettes/day; from US, Europe and Japan) were eligible for participation. RESULTS: Two-compartment linear disposition combined with zero-order absorption model was adequate to describe nicotine pharmacokinetics, and a mono-exponentially decreasing background component was utilized to account for nicotine carry-over effects. Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability). Bioavailability was product-specific, decreased with increasing nicotine ISO yield, and increased with increasing body weight. Absorption duration was apparently prolonged with nicotine gum. The typical initial and terminal half-lives were 1.35 and 17 h, respectively. The presence of menthol did not impact the determinants of the area under the curve. The model adequately described the external validation data. CONCLUSIONS: The population model was able to describe in different populations the nicotine pharmacokinetics after single product use and after 4 days of ad libitum use of Tobacco Heating System, cigarettes, and of different nicotine replacement therapies with various routes of administration.
BACKGROUND AND OBJECTIVE: Characterizing nicotine pharmacokinetics is challenging in the presence of background exposure. We performed a combined retrospective population pharmacokinetic analysis of 8 trials, including exposure to Tobacco Heating System and cigarettes (both inhaled), nicotine nasal spray and oral nicotine gum. METHOD: Data from 4 single product use trials were used to develop a population pharmacokinetic model with Phoenix® NLME™ and to derive exposure parameters. Data from 4 separate ad libitum use studies were used for external validation. A total of 702 healthy adult smokers (54% males; 21-66 years of age; smoking ≥10 cigarettes/day; from US, Europe and Japan) were eligible for participation. RESULTS: Two-compartment linear disposition combined with zero-order absorption model was adequate to describe nicotine pharmacokinetics, and a mono-exponentially decreasing background component was utilized to account for nicotine carry-over effects. Apparent nicotine clearance was typically 0.407 L/min in males and 26% higher in females (68% inter-individual variability). Bioavailability was product-specific, decreased with increasing nicotine ISO yield, and increased with increasing body weight. Absorption duration was apparently prolonged with nicotine gum. The typical initial and terminal half-lives were 1.35 and 17 h, respectively. The presence of menthol did not impact the determinants of the area under the curve. The model adequately described the external validation data. CONCLUSIONS: The population model was able to describe in different populations the nicotine pharmacokinetics after single product use and after 4 days of ad libitum use of Tobacco Heating System, cigarettes, and of different nicotine replacement therapies with various routes of administration.
Authors: M Unverdorben; A Mostert; S Munjal; A van der Bijl; L Potgieter; C Venter; Q Liang; B Meyer; H-J Roethig Journal: Regul Toxicol Pharmacol Date: 2010-03-15 Impact factor: 3.271
Authors: Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale Journal: Clin Pharmacol Ther Date: 2006-11 Impact factor: 6.875
Authors: Hiroshi Yamazaki; Kana Horiuchi; Ryohji Takano; Taku Nagano; Makiko Shimizu; Masato Kitajima; Norie Murayama; Fumiaki Shono Journal: Int J Environ Res Public Health Date: 2010-09-01 Impact factor: 3.390
Authors: Andrew W Bergen; Martha Michel; Denise Nishita; Ruth Krasnow; Harold S Javitz; Karen N Conneely; Christina N Lessov-Schlaggar; Hyman Hops; Andy Z X Zhu; James W Baurley; Jennifer B McClure; Sharon M Hall; Timothy B Baker; David V Conti; Neal L Benowitz; Caryn Lerman; Rachel F Tyndale; Gary E Swan Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240
Authors: Per O Olsson Gisleskog; Juan José Perez Ruixo; Åke Westin; Anna C Hansson; Paul A Soons Journal: Clin Pharmacokinet Date: 2020-12-23 Impact factor: 6.447